How Much Revenue Is Your Pharmacy Losing to Billing Errors?

Pharmacy benefit managers frequently reimburse below maximum allowable cost benchmarks, creating a gap between what should be paid and actual reimbursement. Studies show 15-20% of claims contain pricing discrepancies that favor PBMs. Without daily MAC list comparisons, these underpayments accumulate into six-figure losses annually. Most pharmacies lack the resources to audit every claim against multiple MAC lists, allowing systematic underpayment to continue unnoticed for months or years.

Direct and indirect remuneration fees are applied months after the point of sale, making them nearly impossible to predict at adjudication. The average DIR fee now exceeds $10 per prescription for Medicare Part D claims, but calculation methodologies vary by plan and performance metrics. Pharmacies that don't track DIR fees by payer and plan often discover they've operated at a loss on entire drug categories. Retroactive DIR clawbacks can reach $30,000 to $100,000 quarterly for mid-sized pharmacies.

Between 5-10% of pharmacy claims reject on first submission due to eligibility issues, prior authorization requirements, or data mismatches. Staff often resolve the patient transaction through cash payment or alternative insurance without resubmitting the corrected claim. Each unresubmitted rejection represents a direct loss of the difference between cash price and insurance reimbursement. High-volume pharmacies can accumulate 50-100 unresolved rejections weekly, totaling $75,000 to $150,000 in annual lost revenue.

National Drug Code selection errors occur when pharmacies bill for a different package size, strength, or manufacturer than what was actually dispensed. Generic drugs with dozens of NDC variants create particular risk for mismatches. PBMs reimburse based on the billed NDC, not the dispensed product, so billing a lower-reimbursed NDC costs money on every fill. Audits reveal NDC billing errors in 8-12% of claims at pharmacies without automated NDC verification systems.

Patients with dual coverage require proper coordination of benefits to maximize reimbursement from both primary and secondary payers. Workflow pressures cause staff to skip secondary billing, especially when primary insurance pays an acceptable amount. Secondary payers often cover copays and deductibles, adding $10-$40 per claim. A pharmacy filling 3,000 prescriptions monthly with 15% dual coverage patients loses $54,000 to $216,000 annually by not billing secondary insurance.

Pharmacies participating in 340B contract pharmacy arrangements must accurately identify eligible prescriptions and bill according to specific protocols. Missing 340B eligibility markers or failing to submit claims through proper channels forfeits the significant margin difference between 340B acquisition cost and standard reimbursement. Split-billing errors that send 340B-eligible claims through regular channels are particularly costly. Contract pharmacies processing 500 eligible prescriptions monthly lose $15,000 to $40,000 annually from 340B capture failures.

Medication therapy management, immunizations, point-of-care testing, and other clinical services generate billable revenue beyond product dispensing. Many pharmacies provide these services but never submit claims to payers or bill patients directly. Medicare Part D plans pay $50-$150 per comprehensive medication review, while immunization administration fees range from $15-$45 depending on payer. A pharmacy administering 50 immunizations monthly without proper billing loses $9,000 to $27,000 annually on that service alone.

Pharmacies that don't actively manage purchasing pay more than necessary for inventory, directly impacting margins on every prescription. Failing to compare pricing across wholesalers, missing limited-time promotions, or not utilizing group purchasing organization contracts inflates cost of goods sold. Generic drug pricing fluctuates weekly, and pharmacies without daily price monitoring pay outdated higher prices. Optimizing purchasing typically reduces acquisition costs by 3-7%, translating to $30,000-$70,000 annually for a pharmacy with $1 million in annual drug purchases.

When patients don't pick up prescriptions or return medications, the original claim must be reversed to avoid paying for unbilled product. Pharmacies that don't systematically reverse abandoned prescriptions within payer time limits forfeit the ability to recover those costs. PBMs also initiate chargebacks for various reasons, and pharmacies that don't reconcile these deductions miss opportunities to dispute invalid chargebacks. Unreconciled reversals and chargebacks typically cost pharmacies 1-2% of total revenue, or $20,000-$40,000 annually for a $2 million pharmacy.

When pharmacies can't completely fill a prescription due to inventory limitations, they often provide a partial supply with plans to complete the remainder later. If the completion isn't properly documented and billed, the pharmacy loses revenue on the unbilled portion. This issue intensifies during drug shortages when partial fills become routine. Pharmacies experiencing frequent shortages can have 20-50 uncompleted partial fills at any time, representing $5,000-$15,000 in unbilled inventory that's already been dispensed.